Laboratory Corporation of America Holdings (LH)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands 5,331,200 5,352,100 3,047,300 3,047,600 4,054,700 4,427,600 5,042,400 5,052,300 5,038,800 5,334,300 5,360,300 5,383,300 5,416,500 5,417,200 5,422,600 4,920,900 5,419,000 5,417,300 5,416,600 5,790,200
Total stockholders’ equity US$ in thousands 8,052,200 8,170,200 8,005,800 7,959,600 7,875,000 7,873,100 8,785,000 8,785,000 10,096,600 10,092,200 10,400,700 10,721,100 10,273,400 10,601,400 10,322,000 10,098,400 9,436,600 8,239,100 7,352,700 7,020,100
Debt-to-equity ratio 0.66 0.66 0.38 0.38 0.51 0.56 0.57 0.58 0.50 0.53 0.52 0.50 0.53 0.51 0.53 0.49 0.57 0.66 0.74 0.82

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $5,331,200K ÷ $8,052,200K
= 0.66

The debt-to-equity ratio of Laboratory Corporation of America Holdings has shown a downward trend from 0.82 as of March 31, 2020, to 0.66 as of December 31, 2024, indicating a decreasing reliance on debt financing in relation to equity over the analyzed period.

The ratio decreased steadily from March 31, 2020, to March 31, 2024, reflecting a consistent effort to lower debt levels in proportion to equity. However, there was a slight increase in the ratio in September 30, 2024, which indicates a temporary uptick in debt relative to the equity position at that point in time.

Overall, the decreasing trend in the debt-to-equity ratio suggests that Laboratory Corporation of America Holdings has been managing its debt levels effectively and may be reducing financial risk by relying more on equity financing compared to debt.


Peer comparison

Dec 31, 2024

Company name
Symbol
Debt-to-equity ratio
Laboratory Corporation of America Holdings
LH
0.66
Fortrea Holdings Inc.
FTRE
0.77
Fulgent Genetics Inc
FLGT
0.00
Quest Diagnostics Incorporated
DGX
0.70
RadNet Inc
RDNT
1.10